Spectranetics Names General Manager of Vascular Intervention

The Spectranetics Corporation announced that Scott Hutton has been named general manager of Vascular Intervention, effective Jan. 23. Hutton will report directly to Scott Drake, president and CEO.
 
Hutton brings a wealth of industry experience and leadership to Spectranetics. He spent the last 16 years with Medtronic plc, most recently leading the Neurosurgery business unit as the vice president and general manager. Prior to joining the Neurosurgery business, Scott led Medtronic Navigation, a provider of integrated navigation and intra-operative imaging solutions. He also held numerous global marketing and business development roles of increasing responsibility during his tenure at Medtronic.
 
“We are pleased to name industry veteran Scott Hutton as the leader of our Vascular Intervention franchise,” said Drake. “Scott’s track record of creating value makes him the ideal candidate to capitalize on our opportunities and lead the Vascular Intervention business through its next phase of growth. We are excited to unite his expertise with our team to further improve the lives of our patients.”
 
Hutton said, “I’m excited for the opportunity to play such a vital role in helping Spectranetics achieve its next stage of growth. The Vascular Intervention franchise is an attractive business with growth opportunities that will be integral to the future success of the company. I’m also proud to be joining Spectranetics’ commitment to leading the way in clinical science in order to provide physicians and patients with proven treatment algorithms and advancements in therapy options.”
 
The Spectranetics Corporation develops, manufactures, markets and distributes medical devices used in minimally invasive procedures within the cardiovascular system. The company’s products are available in more than 65 countries and are used to treat arterial blockages in the heart and legs and in the removal of pacemaker and defibrillator leads. The company’s Vascular Intervention (VI) products include a range of laser catheters for ablation of blockages in arteries above and below the knee, the AngioSculpt scoring balloon used in both peripheral and coronary procedures, and the Stellarex drug-coated balloon peripheral angioplasty platform, which received European CE mark approval in December 2014. The company also markets support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions. The Colorado Springs, Colo.-based company markets aspiration and cardiac laser catheters to treat blockages in the heart. The Lead Management (LM) product line includes excimer laser sheaths, dilator sheaths, mechanical sheaths and accessories for the removal of pacemaker and defibrillator cardiac leads.